Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Insight Molecular Diagnostics has disclosed Liabilities from Discontinued Operations across 3 years of filings, most recently posting 45000.0 for Q4 2023.

• Liabilities from Discontinued Operations for Q4 2023 came in at 45000.0, down 97.76% year-over-year; the trailing twelve-month figure through Dec 2023 was 45000.0 (down 97.76% YoY), and the FY2023 annual result was 45000.0, down 97.76% from the prior year.
• Liabilities from Discontinued Operations came in at 45000.0 for Q4 2023 at Insight Molecular Diagnostics, down from 90000.0 in the prior quarter.
• In the past five years, Liabilities from Discontinued Operations ranged from a high of 2005000.0 in Q4 2022 to a low of 45000.0 in Q4 2023.
• The 3-year median for Liabilities from Discontinued Operations is 185500.0 (2023), against an average of 672833.33.
• Across the five-year window, Liabilities from Discontinued Operations soared 31.39% in 2022 and slumped 97.76% in 2023, its largest moves.
• Insight Molecular Diagnostics' Liabilities from Discontinued Operations stood at 1526000.0 in 2021, then jumped by 31.39% to 2005000.0 in 2022, then plunged by 97.76% to 45000.0 in 2023.
• The last three Liabilities from Discontinued Operations figures came in at 45000.0 (Q4 2023), 90000.0 (Q3 2023), and 135000.0 (Q2 2023), per Business Quant data.